The board of directors of Uni-Bio Science Group Limited announced the acceptance of its marketing application for Diquafosol Sodium eye drops by the China National Medical Products Administration (NMPA), with the acceptance number CYHS2400318. This acceptance marks a pivotal step in expanding the Group's ophthalmology drug repertoire and providing patients with more diverse treatment options upon successful marketing approval. Diquafosol sodium eye drops complement the Group's robust ophthalmic drug portfolio, following GeneSoft, which is expected to be approved for marketing in the first quarter of 2025.

Aligned with the surging demand within China's ophthalmic drug market, the Group identifies the significant potential, as over 360 million patients suffer from dry eye disease in the country. Zhuoshi Consulting forecasts that the market for dry eye medication is expected to experience substantial growth, reaching over CNY 42 billion by 2030, expanding at a compound annual growth rate of 28.4%. Diquafosol Sodium represents the next generation of dry eye medication, offering cutting-edge therapy through its novel mechanism as a P2Y2 receptor agonist to stimulate tear and mucin secretion, addressing the underlying causes of dry eye syndrome, normalizing the tear layer and improving corneal epithelial damage.

Since the introduction of the original imported version in Japan in 2010 and its subsequent arrival in China in 2017, anticipation has grown for domestic product launches that will likely increase market penetration and sales volume. To capitalize on this opportunity, the Group has undertaken a strategic expansion of its sales force, which has more than doubled in size this year. The Group has also adopted a forward-thinking sales strategy, integrating online e-commerce platforms to diversify sales channels and enhance customer engagement.

This approach is set to reinforce the Group's stronghold within the ophthalmology market.